Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels.
about
Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursorSearching for the physiological role of glucose-dependent insulinotropic polypeptideDiscovery of gastric inhibitory polypeptide and its subsequent fate: Personal reflectionsVaccination against GIP for the treatment of obesityChronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic ratsRegulation of glucose-dependent insulinotropic polypeptide release by protein in the rat.Significance of Microbiota in Obesity and Metabolic Diseases and the Modulatory Potential by Medicinal Plant and Food IngredientsEffect of endogenous GLP-1 on insulin secretion in type 2 diabetes.Assessment of the effects of insulin secretagogues in humans.A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodentsThe vagus nerve, food intake and obesity.Incretins, insulin secretion and Type 2 diabetes mellitus.Gastric bypass alters both glucose-dependent and glucose-independent regulation of islet hormone secretion.Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test.Interaction of fat-stimulated gastric inhibitory polypeptide on pancreatic alpha and beta cell function.Gut hormones in glucose homeostasis.Physiology and pathophysiology of GIP: a review.Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestionThe glucose-dependent insulinotropic polypeptide and glucose-stimulated insulin response to exercise training and diet in obesityThe Incretins and Pancreatic beta-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus.Advances in the etiology and management of hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass.The postprandial response of gastric inhibitory polypeptide to various dietary fats in man.New developments in the incretin concept.Hormones and metabolism: a background.Gastric inhibitory polypeptide: physiology and novel aspects.Cephalic phase, reflex insulin secretion. Neuroanatomical and physiological characterization.Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreasNutrient-induced secretion and metabolic effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.Gastric inhibitory polypeptide (GIP).The influence of body weight, age and glucose tolerance on the relationship between GIP secretion and beta-cell function in man.How laboratory dogs accommodate meals of different size but similar composition.Pancreatic alpha- and beta-cell responses to GIP infusion in normal man.Interaction of arginine and gastric inhibitory polypeptide on insulin release in man.Augmentation of alimentary insulin secretion despite similar gastric inhibitory peptide (GIP) responses in juvenile obesity.Different effects of bombesin on glucose- and tolbutamide-induced insulin release in man.Carbachol modulates GIP-mediated insulin release from rat pancreatic lobules in vitro.Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.Influence of ingested load on postprandial insulin secretion. Rôle of gastric inhibitory polypeptide (GIP).Allyl isothiocyanate increases carbohydrate oxidation through enhancing insulin secretion by TRPV1.Correlation of the incretin effect with first- and second-phase insulin secretions in Koreans with various glucose tolerance statuses.
P2860
Q24293668-C475B0B2-8080-4B1A-9EEA-522F215BC662Q26749221-266BBF1A-BFDC-4953-BA8E-A9F40E4C2C0DQ26749226-BA727D40-6C9B-427B-BD39-3B1DF256AE62Q27300376-833520E9-BFDD-4CAD-A0D9-D554BAC4DB58Q28570330-940E14E4-1E20-4C08-83FC-3E9E4DA84DFBQ30911748-7ADE18D7-085F-40CB-9402-837B3ACCC37BQ33858968-DBB6D480-0B20-4B17-8968-FAD7546E61D0Q33869732-0671BF49-D03E-4BDC-9116-ED895AA9002CQ34166369-57B8A056-5276-43D8-83B8-6B474A78492AQ34540961-364BD980-E8AF-4E79-8C06-25591E205E0AQ34778864-DE0976A0-81B3-443C-8599-0D5752808E2FQ35669308-59901711-07F1-4505-A1F5-BF5492A4E5D0Q36101563-31CF53CA-74D4-416C-A70F-94D50B4E2A4CQ36339659-9B2984FE-2D1A-45D5-BC82-ED655508BD14Q37022441-D732CBC8-A7B9-4D8C-A0DE-0E3C668DD348Q37039925-D2963FD6-7C06-4202-8EA0-507AC54875BFQ37040026-8CA609E2-4F3B-464B-A425-F0477ECD5CC4Q37061286-4BE1122E-729B-4D49-BBD0-AF4CE2F65F27Q37216719-44B2E560-2554-43D4-BFCE-16E932B48D52Q37763540-B5EF7D67-9894-49EA-86C1-02589FB9E6A1Q37889178-98ED0146-AE4F-4B33-BA06-14D3E99E7172Q38594389-EDD1E196-A8B2-4650-8E57-E0DF5E176220Q39832287-528D55DC-7AB3-4A31-BA4C-0175DD14ECB8Q40091218-4A854586-2738-473B-8600-3D4D9B71EE7BQ40093946-473F29B8-901E-4C4A-A05D-2420097F0EB6Q40305590-65A4CAF7-A93D-4E6A-97C9-943960BF7C77Q40920945-8CDF3695-6A97-40A8-AE69-01D5CFCEB8DAQ41131972-89D42F38-CCAE-4342-8206-7D60567CFE72Q41202334-88821E53-1CE8-4A98-A805-07FB6083174CQ41294213-F5CA99E5-9394-4B9E-838C-CDE506D58F0EQ41503494-9795C1B2-58B8-4BFB-92B6-CCE721480CD7Q41719571-F5649289-93B8-47A4-AD2C-C563F4E8FF66Q42467618-4902752B-BE4C-4133-A5CF-AF904B5CE874Q42488086-09B1DE47-70CF-4A2B-85B5-A9AF91AFD358Q42848753-5414B527-849F-4A39-B08D-4E2B74FAF785Q44997126-F501BB31-7575-4535-9CE5-4536FD84084FQ45985301-215B8F99-6301-4CFC-9EC3-8147ECA4594CQ46367304-AD30CB4B-0583-4EFE-AF8C-DD43D36BE8F3Q50061955-346038C2-8295-4437-A5E5-2AAC165ED9D7Q51031191-813455C4-3675-4009-8A16-05DE83515A31
P2860
Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 1978
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Oral glucose augmentation of i ...... nt glucose and insulin levels.
@en
Oral glucose augmentation of i ...... nt glucose and insulin levels.
@nl
type
label
Oral glucose augmentation of i ...... nt glucose and insulin levels.
@en
Oral glucose augmentation of i ...... nt glucose and insulin levels.
@nl
prefLabel
Oral glucose augmentation of i ...... nt glucose and insulin levels.
@en
Oral glucose augmentation of i ...... nt glucose and insulin levels.
@nl
P2093
P2860
P921
P356
P1476
Oral glucose augmentation of i ...... nt glucose and insulin levels.
@en
P2093
P2860
P304
P356
10.1172/JCI109100
P407
P577
1978-07-01T00:00:00Z